Analyzing Oncocyte (IMDX) and The Competition

Oncocyte (NASDAQ:IMDX) is one of 857 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Oncocyte to similar businesses based on the strength of its institutional ownership, earnings, analyst recommendations, valuation, profitability, risk and dividends.

Insider & Institutional Ownership

55.3% of Oncocyte shares are owned by institutional investors. Comparatively, 48.2% of shares of all “Biotechnology” companies are owned by institutional investors. 2.2% of Oncocyte shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Oncocyte and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,955.63%	N/A	-107.52%
Oncocyte Competitors	-9,423.55%	-126.75%	-33.08%

Earnings & Valuation

This table compares Oncocyte and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Oncocyte	$1.67 million	-$50.22 million	-2.70
Oncocyte Competitors	$741.69 million	$17.04 million	-11.22

Oncocyte’s rivals have higher revenue and earnings than Oncocyte. Oncocyte is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Oncocyte has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500. Comparatively, Oncocyte’s rivals have a beta of 1.10, suggesting that their average share price is 10% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Oncocyte and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1	0	2	0	2.33
Oncocyte Competitors	9450	14941	44764	1515	2.54

Oncocyte currently has a consensus price target of $10.50, indicating a potential upside of 161.32%. As a group, “Biotechnology” companies have a potential upside of 67.95%. Given Oncocyte’s higher probable upside, equities research analysts plainly believe Oncocyte is more favorable than its rivals.

Summary

Oncocyte beats its rivals on 7 of the 13 factors compared.

Oncocyte Company Profile

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.